Elderly Spared Jail for Killing Wife with Parkinson’s Disease in ‘Act of Mercy’

US Supreme Court building in Washington (AP Photo, File)
US Supreme Court building in Washington (AP Photo, File)
TT

Elderly Spared Jail for Killing Wife with Parkinson’s Disease in ‘Act of Mercy’

US Supreme Court building in Washington (AP Photo, File)
US Supreme Court building in Washington (AP Photo, File)

An 82-year-old man has been spared jail for killing his wife who suffered from Parkinson’s disease in an “act of mercy,” reported Sky News.

Martin Rudin admitted killing retired teacher Gabriella Rudin, 75, at their home in Histon, Cambridgeshire, early last New Year’s Eve.

She had recently returned from hospital after suffering a fall and had told her son the day before her death she wanted to “go to Belgium” to die.

Rudin, a retired civil engineer, handed himself into police on January 9, telling officers his third wife had been “begging” him to kill her and said: “I just couldn’t bear it any longer, for her or me.”

He denied murder but admitted manslaughter by diminished responsibility, which was accepted by prosecutors, and was sentenced on Thursday to two years imprisonment, suspended for two years.

Judge Mark Bishop said the “tragic case” involved a couple - who had been married for 11 years after meeting online - who had led a “loving and content, interesting life together.”

The judge said Rudin was not coping with the “strain of being the principal carer,” adding: “I accept at the time he did believe he was doing what he believed to be an act of mercy.”

“It is clear Mrs. Rudin had been speaking of wanting to die and I accept the defendant was overwhelmed by her expression of wanting to die, given his depressed state,” he continued.

The judge said that while frail and vulnerable people needed the protection of the law, “the facts of the case require the court to take a merciful course.”

Mrs. Rudin was diagnosed with Parkinson’s disease in 2018, was admitted to hospital after a fall last December, and was prescribed antidepressants before being discharged on Christmas Eve.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”